231 related articles for article (PubMed ID: 22257063)
1. Gemcitabine: a critical nucleoside for cancer therapy.
Gesto DS; Cerqueira NM; Fernandes PA; Ramos MJ
Curr Med Chem; 2012; 19(7):1076-87. PubMed ID: 22257063
[TBL] [Abstract][Full Text] [Related]
2. Nucleoside and nucleobase analogs in cancer treatment: not only sapacitabine, but also gemcitabine.
Muggia F; Diaz I; Peters GJ
Expert Opin Investig Drugs; 2012 Apr; 21(4):403-8. PubMed ID: 22404148
[TBL] [Abstract][Full Text] [Related]
3. Role of deoxycytidine kinase (dCK) activity in gemcitabine's radioenhancement in mice and human cell lines in vitro.
Grégoire V; Rosier JF; De Bast M; Bruniaux M; De Coster B; Octave-Prignot M; Scalliet P
Radiother Oncol; 2002 Jun; 63(3):329-38. PubMed ID: 12142097
[TBL] [Abstract][Full Text] [Related]
4. Preclinical characteristics of gemcitabine.
Plunkett W; Huang P; Gandhi V
Anticancer Drugs; 1995 Dec; 6 Suppl 6():7-13. PubMed ID: 8718419
[TBL] [Abstract][Full Text] [Related]
5. [Non-clinical studies of gemcitabine--the mode of action and antitumor activities].
Tsukagoshi S
Gan To Kagaku Ryoho; 1999 Feb; 26(3):393-400. PubMed ID: 10065109
[TBL] [Abstract][Full Text] [Related]
6. Gemcitabine: a cytidine analogue active against solid tumors.
Hui YF; Reitz J
Am J Health Syst Pharm; 1997 Jan; 54(2):162-70; quiz 197-8. PubMed ID: 9117804
[TBL] [Abstract][Full Text] [Related]
7. [Metabolism, mechanism of action and resistance to cytotoxic nucleoside analogues].
Jordheim LP; Galmarini CM; Dumontet C
Bull Cancer; 2005 Mar; 92(3):239-48. PubMed ID: 15820918
[TBL] [Abstract][Full Text] [Related]
8. Gemcitabine monotherapy in recurrent ovarian cancer: from the bench to the clinic.
Bookman MA
Int J Gynecol Cancer; 2005; 15 Suppl 1():12-7. PubMed ID: 15839953
[TBL] [Abstract][Full Text] [Related]
9. Synthesis and biological activity of a gemcitabine phosphoramidate prodrug.
Wu W; Sigmond J; Peters GJ; Borch RF
J Med Chem; 2007 Jul; 50(15):3743-6. PubMed ID: 17602464
[TBL] [Abstract][Full Text] [Related]
10. Regulation of phosphorylation of deoxycytidine and 2',2'-difluorodeoxycytidine (gemcitabine); effects of cytidine 5'-triphosphate and uridine 5'-triphosphate in relation to chemosensitivity for 2',2'-difluorodeoxycytidine.
van Haperen VW; Veerman G; Vermorken JB; Pinedo HM; Peters G
Biochem Pharmacol; 1996 Apr; 51(7):911-8. PubMed ID: 8651941
[TBL] [Abstract][Full Text] [Related]
11. Pharmacological factors affecting accumulation of gemcitabine's active metabolite, gemcitabine triphosphate.
Rizzuto I; Ghazaly E; Peters GJ
Pharmacogenomics; 2017 Jun; 18(9):911-925. PubMed ID: 28594276
[TBL] [Abstract][Full Text] [Related]
12. Algorithmic modeling quantifies the complementary contribution of metabolic inhibitions to gemcitabine efficacy.
Kahramanoğullari O; Fantaccini G; Lecca P; Morpurgo D; Priami C
PLoS One; 2012; 7(12):e50176. PubMed ID: 23239976
[TBL] [Abstract][Full Text] [Related]
13. Nucleoside-catabolizing enzymes in mycoplasma-infected tumor cell cultures compromise the cytostatic activity of the anticancer drug gemcitabine.
Vande Voorde J; Sabuncuoğlu S; Noppen S; Hofer A; Ranjbarian F; Fieuws S; Balzarini J; Liekens S
J Biol Chem; 2014 May; 289(19):13054-65. PubMed ID: 24668817
[TBL] [Abstract][Full Text] [Related]
14. Nucleoside analogues: mechanisms of drug resistance and reversal strategies.
Galmarini CM; Mackey JR; Dumontet C
Leukemia; 2001 Jun; 15(6):875-90. PubMed ID: 11417472
[TBL] [Abstract][Full Text] [Related]
15. Gemcitabine: metabolism, mechanisms of action, and self-potentiation.
Plunkett W; Huang P; Xu YZ; Heinemann V; Grunewald R; Gandhi V
Semin Oncol; 1995 Aug; 22(4 Suppl 11):3-10. PubMed ID: 7481842
[TBL] [Abstract][Full Text] [Related]
16. Role of deoxycytidine kinase (dCK), thymidine kinase 2 (TK2), and deoxycytidine deaminase (dCDA) in the antitumor activity of gemcitabine (dFdC).
Kroep JR; van Moorsel CJ; Veerman G; Voorn DA; Schultz RM; Worzalla JF; Tanzer LR; Merriman RL; Pinedo HM; Peters GJ
Adv Exp Med Biol; 1998; 431():657-60. PubMed ID: 9598147
[No Abstract] [Full Text] [Related]
17. Gemcitabine: a pharmacologic and clinical overview.
Barton-Burke M
Cancer Nurs; 1999 Apr; 22(2):176-83. PubMed ID: 10217035
[TBL] [Abstract][Full Text] [Related]
18. Cellular pharmacology of gemcitabine.
Mini E; Nobili S; Caciagli B; Landini I; Mazzei T
Ann Oncol; 2006 May; 17 Suppl 5():v7-12. PubMed ID: 16807468
[TBL] [Abstract][Full Text] [Related]
19. Attenuation of phosphorylation by deoxycytidine kinase is key to acquired gemcitabine resistance in a pancreatic cancer cell line: targeted proteomic and metabolomic analyses in PK9 cells.
Ohmine K; Kawaguchi K; Ohtsuki S; Motoi F; Egawa S; Unno M; Terasaki T
Pharm Res; 2012 Jul; 29(7):2006-16. PubMed ID: 22419259
[TBL] [Abstract][Full Text] [Related]
20. Mechanistic Multiscale Pharmacokinetic Model for the Anticancer Drug 2',2'-difluorodeoxycytidine (Gemcitabine) in Pancreatic Cancer.
Garcia-Cremades M; Melillo N; Troconiz IF; Magni P
Clin Transl Sci; 2020 May; 13(3):608-617. PubMed ID: 32043298
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]